Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG).
EGFR
genetic mapping
mutations
nab-paclitaxel
pancreatic cancer
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
04
2019
revised:
24
05
2019
accepted:
25
05
2019
entrez:
2
11
2019
pubmed:
2
11
2019
medline:
2
11
2019
Statut:
epublish
Résumé
Pancreatic cancer is one of the most fatal malignancies ranking fourth among the leading causes of cancer death with diagnosis at late stages carrying a dismal prognosis. The aim of our retrospective study was to describe the nature and the incidence of gene mutations and genomic instability in advanced pancreatic adenocarcinomas of a Greek patient population fully annotated with clinicopathological data. We used a targeted next-generation sequencing (NGS) panel encompassing genes commonly mutated in pancreatic tumours in a patient population managed with either nab-paclitaxel regimens or targeted compounds modulating the epidermal growth factor receptor (EGFR)/AKT/mTOR axis. We identified
Identifiants
pubmed: 31673425
doi: 10.1136/esmoopen-2019-000525
pii: S2059-7029(20)30118-6
pmc: PMC6802956
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e000525Informations de copyright
© Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.
Déclaration de conflit d'intérêts
Competing interests: VKa: Advisory Board of Amgen, Pfizer, Novartis, BI, Lilly, Astellas, Genesis-Pharma and Janssen. ES: Advisory Board of Merck, MSD, Asta-Zeneca, Roche, Amgen and Genesis. GF: Advisory Board of Pfizer, Sanofi and Roche. Honoraria from Astra-Zeneca. GP: Advisory Role: Roche, Honoraria: Roche, Speaker bureau: Roche, Grants: Amgen.
Références
Genet Med. 2015 Jul;17(7):569-77
pubmed: 25356972
Oncotarget. 2017 Dec 25;9(4):5274-5286
pubmed: 29435178
J Epidemiol Community Health. 2007 Jul;61(7):641-9
pubmed: 17568059
Cancers (Basel). 2017 Apr 28;9(5):null
pubmed: 28452926
Sci Transl Med. 2015 Apr 15;7(283):283ra54
pubmed: 25877892
In Vivo. 2018 Nov-Dec;32(6):1527-1531
pubmed: 30348712
Int J Oncol. 2018 Jun;52(6):1972-1980
pubmed: 29620163
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Hered Cancer Clin Pract. 2018 Mar 7;16:7
pubmed: 29541281
Nat Commun. 2015 Apr 09;6:6744
pubmed: 25855536
PLoS One. 2017 Jul 25;12(7):e0181532
pubmed: 28742845
J Thorac Oncol. 2012 Apr;7(4):773-4; author reply 774
pubmed: 22425934
Br J Cancer. 2014 Aug 26;111(5):817-22
pubmed: 24755884
Cancer J. 2017 Nov/Dec;23(6):321-325
pubmed: 29189327
Ann Oncol. 2017 Apr 1;28(4):741-747
pubmed: 28104621
J Gastrointest Oncol. 2016 Oct;7(5):738-749
pubmed: 27747088
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Curr Drug Targets. 2018;19(1):21-37
pubmed: 28699513
Lung Cancer. 2014 Feb;83(2):163-7
pubmed: 24331409
Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008
pubmed: 20182602
Pancreas. 2015 Apr;44(3):484-92
pubmed: 25513781
Carcinogenesis. 2007 Aug;28(8):1794-9
pubmed: 17575320
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
Eur J Cancer. 2016 Feb;54:75-83
pubmed: 26735353
World J Clin Oncol. 2017 Jun 10;8(3):230-240
pubmed: 28638792
Pancreas. 2017 Mar;46(3):335-340
pubmed: 28099251
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Clin Cancer Res. 2009 Jul 15;15(14):4674-9
pubmed: 19584151